← FDA DRUG APPROVALS

FDA ANDA · ANDA208052

LURASIDONE HYDROCHLORIDE

Sponsor: ZYDUS PHARMS

APPLICATION
ANDA208052
TYPE
ANDA
ORIGINAL APPROVAL
2019-03-19
LATEST ACTION
2026-05-14
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LURASIDONE HYDROCHLORIDEPrescription
LURASIDONE HYDROCHLORIDE 80MG · TABLET · ORAL
LURASIDONE HYDROCHLORIDEPrescription
LURASIDONE HYDROCHLORIDE 40MG · TABLET · ORAL
LURASIDONE HYDROCHLORIDEPrescription
LURASIDONE HYDROCHLORIDE 120MG · TABLET · ORAL
LURASIDONE HYDROCHLORIDEPrescription
LURASIDONE HYDROCHLORIDE 60MG · TABLET · ORAL
LURASIDONE HYDROCHLORIDEPrescription
LURASIDONE HYDROCHLORIDE 20MG · TABLET · ORAL

Approval history

2026-05-14Labeling · Supplement 5 · standardAP
2023-07-21Labeling · Supplement 1 · standardAP
2019-03-19UNKNOWN · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →